Artificial Intelligence in Drug Discovery Market-Overview
The incorporation of AI and machine learning tools in drug discovery and development applications can improve healthcare outcomes by enhancing overall efficiency. As per MRFR, the Artificial Intelligence in Drug Discovery Market is estimated to gain a USD 2,015.1 Million with a CAGR of 40.8% by 2025.
Artificial intelligence in healthcare is thriving, and with the endless possibilities given by this advanced technology, a growing number of industry titans are taking an interest and investing money into healthcare applications. In the projected period, the market will be further motivated by the development of AI and machine learning techniques for the enhancement of drug discovery and drug development results.
By application, the market consists of target identification, de novo drug designing, drug optimization and repurposing, candidate screening, and preclinical testing. By molecule type, the market consists of large and small molecules. By technology, the market consists of deep learning and machine learning. By indication, the market consists of immune-oncology, cardiovascular diseases, metabolic diseases, and neurodegenerative diseases. By product type, the market consists of software and services.
Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/9393
Detailed Regional Analysis
Over the years, countries such as the United States and Canada have been at the forefront of the healthcare business. One of the primary reasons for the region’s quick growth in the AI in drug discovery market is the increasing presence of large AI platform developers. After the Americas, Europe is the second-largest market for AI in drug discovery. Collective R&D efforts in the pharma sector and strong demand for AI solutions by Big Pharma organizations are some of the reasons projected to drive the regional AI in the drug discovery market. The collective demand for effective drug discovery solutions can be attributed to the growth of Asia-Pacific artificial intelligence in the drug discovery market. Several startups are working to integrate AI applications in drug discovery.
The overall development prospects of market participants are predicted to boost progressively as the impact of the COVID-19 epidemic lessens. The emergence of global firms into important developing regional markets is considered to have a positive impact that will spread to other industry segments. The involvement of governmental organizations in promoting market development is projected to be critical through the provision of special incentives to attract global titans to certain locations and contribute to market development during the forecast period. The effectiveness of core sectors on a global scale is projected to augment the expansion of the global market in the approaching period. Furthermore, improved economic relations between numerous nations are expected to provide opportunities for growth in the coming years. The optimism about COVID-19-related therapeutic techniques, such as vaccines, being pushed out in various locations is forecast to expand market sentiment further.
The prominent companies in the artificial intelligence in drug discovery market are IBM Corporation, Envisagenics, Google, Atomwise, Inc., Deep Genomics, Insilico Medicine, BenevolentAI, Cyclica, Bioage, Numerate, Microsoft Corporation, Numedii, Inc., Twoxar, Incorporated, Owkin, Inc., Exscientia, Cloud Pharmaceuticals, Inc., Xtalpi, Inc., Verge Genomics, Berg LLC.
Ask Questions To The Experts @ https://www.marketresearchfuture.com/enquiry/9393
Dec 2021 Insilico Medicine, a firm that leverages artificial intelligence in medication discovery, has reported the administration of ISM001-055 to the first healthy volunteer in a microdose experiment. The medicine is a small-molecule inhibitor of a novel biological target discovered by Pharma.AI, the company’s artificial intelligence-powered drug development platform (AI). ISM001-055 is being developed to treat idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes a progressive, irreversible decrease in lung function. In the research, which is being undertaken in Australia, ISM001-055 is being administered intravenously to healthy volunteers.
Table Of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global AI In Drug Discovery Market, By Product Type
1.1.2. Global AI In Drug Discovery Market, By Molecule Type
1.1.3. Global AI In Drug Discovery Market, By Technology
1.1.4. Global AI In Drug Discovery Market, By Indication
1.1.5. Global AI In Drug Discovery Market, By Application
1.1.6. Global AI In Drug Discovery Market, By End User
2. MARKET INTRODUCTION
2.2. Scope Of The Study
2.2.1. Research Objective
3. RESEARCH METHODOLOGY
3.2. Data Mining
3.2.1. Secondary Research
3.2.2. Primary Research
126.96.36.199. Breakdown Of Primary Respondents
3.2.3. Forecasting Techniques
3.3. Research Methodology For Market Size Estimation
3.3.1. Bottom-Up Approach
3.3.2. Top-Down Approach
3.4. Data Triangulation
4. MARKET DYNAMICS
5. MARKET FACTOR ANALYSIS
Browse Complete Report @ https://www.marketresearchfuture.com/reports/ai-drug-discovery-market-9393
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America